Meltzer H Y, Luchins D J
J Clin Psychopharmacol. 1984 Oct;4(5):286-7.
There have been conflicting reports as to whether clozapine, an atypical antipsychotic, will suppress symptoms of tardive dyskinesia. With this in mind, the authors present the case of a 32-year-old chronically institutionalized schizophrenic who showed a remarkable improvement in both tardive dyskinesia and psychotic symptoms following an open trial of clozapine, 900 mg daily. This effect was noted to persist throughout the 15-month observation period with no breakthrough dyskinesia. The ability of clozapine to suppress tardive dyskinesia symptoms raises the possibility that clozapine, at least at the doses used in this report, might also induce the disorder. Long-term, controlled studies are required to specifically address this issue.
关于非典型抗精神病药物氯氮平是否会抑制迟发性运动障碍症状,一直存在相互矛盾的报道。考虑到这一点,作者报告了一例32岁长期住院的精神分裂症患者,在进行了每日900毫克氯氮平的开放试验后,迟发性运动障碍和精神病症状均有显著改善。在整个15个月的观察期内,这种效果持续存在,没有出现突破性运动障碍。氯氮平抑制迟发性运动障碍症状的能力增加了一种可能性,即至少在本报告中使用的剂量下,氯氮平也可能诱发该疾病。需要进行长期的对照研究来具体解决这个问题。